Drugs / Anti-CD22-CAR-transduced T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03262298 | Aug 2017 → Aug 2021 | leukemia, lymphoma | Affiliated Hospital to Academy of Military Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT02935153 | Oct 2016 → Oct 2019 | leukemia, lymphoma | Southwest Hospital, China | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD22-CAR-transduced T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02935153 ↗ |
| Known as | anti-CD22 CART | “anti-CD22 CART, CART22” NCT03262298 ↗ |
| Known as | CART22 | “anti-CD22 CART, CART22” NCT03262298 ↗ |
| Modality | Cell therapy | “autologous-derived CD22-targeted CAR-T cells” NCT02935153 ↗ |
| Target | CD22 | “CD22-targeted chimeric antigen receptor modified-T cell(CAR-T) cells” NCT03262298 ↗ |